BlueWillow Biologics
  • Home
  • NanoVax Platform
    • Technology
    • Intranasal
    • Human Clinical Evidence
  • Company
    • About BlueWillow Biologics
    • Leadership Team
    • Contact
  • Press Room
    • News
    • Scientific Publications
  • Menu Menu

News

  • H5 Influenza (Pandemic Flu) Clinical Trial Successful, Peer-Reivewed and Accepted for Publication
  • BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
  • Dr. Shabaana Khader, University of Chicago, highlights promise of intranasal mucosal vaccine strategy for tuberculosis.

Contact

BlueWillow Biologics, Inc. 

2311 Green Rd. Suite A
Ann Arbor, MI 48105

734-302-4000
734-302-9150 fax

Scroll to top Scroll to top Scroll to top